Experimental browser for the Atmosphere
Loading post...
{ "uri": "at://did:plc:naykhjvftrs236tkc2ku3ma7/app.bsky.feed.like/3loc3xohxfk2y", "cid": "bafyreicpjxvocqf2y4wksrg6ufeinmbkpy2cjazzxpvpvyyg7kujtjho3q", "value": { "$type": "app.bsky.feed.like", "subject": { "cid": "bafyreidyhpkoxnb7jzpptwedc4i5b7essexwyhye4uvrremwg4wbbqo2va", "uri": "at://did:plc:plgt5bqnko7dwhzi2436ipuf/app.bsky.feed.post/3lmupuu2kue2q" }, "createdAt": "2025-05-03T19:43:32.205Z" } }
Ibrutinib+nivo in R/R CNS lymphoma - 18 pts: 16 PCNSL, 2 SCNSL, none concurrent systemic dx, 11 non-GC - ORR 78%, CR 50% (non-GC: ORR 91%, CR 45%) - 1-yr PFS 42%, OS 63%, 3 pts in remission for >2 yrs - 55% irAEs Bridging option to consolidation? #lymsm buff.ly/C6lf349
Apr 15, 2025, 6:37 PM